Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Evommune, Inc. ( (EVMN) ) has provided an announcement.
On Feb. 10, 2026, Evommune reported positive top-line data from a randomized, double-blind, placebo-controlled Phase 2a trial of its long-acting fusion protein EVO301 in 70 adults with moderate-to-severe atopic dermatitis. The intravenous regimen met its primary EASI-based efficacy endpoint with a 33% placebo-adjusted improvement at week 12, showed rapid statistically significant EASI reductions at weeks 4, 8 and 12, and achieved vIGA-AD 0/1 in 23% of treated patients versus none on placebo.
EVO301 demonstrated a favorable safety profile with no related serious or severe adverse events, no treatment-related discontinuations, pharmacokinetics consistent with a once-every-four-weeks dosing schedule, and robust reductions in Th2 and non-Th2 inflammatory biomarkers. The strong proof-of-concept results validate IL-18 inhibition as a therapeutic strategy, support Evommune’s plan to advance EVO301 into a Phase 2b dose-ranging trial and explore additional indications such as ulcerative colitis, and reinforce the company’s ambitions to expand its presence in the immunology space.
The most recent analyst rating on (EVMN) stock is a Sell with a $17.00 price target. To see the full list of analyst forecasts on Evommune, Inc. stock, see the EVMN Stock Forecast page.
Spark’s Take on EVMN Stock
According to Spark, TipRanks’ AI Analyst, EVMN is a Neutral.
The score is primarily held down by weak financial performance: widening losses, accelerating cash burn, and a highly leveraged balance sheet with negative equity. Technicals provide some offset with positive near-term momentum (price above DMA20 and positive MACD), but valuation cannot be meaningfully assessed due to missing P/E and dividend yield data.
To see Spark’s full report on EVMN stock, click here.
More about Evommune, Inc.
Evommune, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies that target key drivers of chronic inflammatory diseases. The company is advancing a portfolio of differentiated product candidates, including fusion proteins such as EVO301, aimed at improving daily life and preventing long-term consequences of uncontrolled inflammation for patients with conditions like atopic dermatitis.
Average Trading Volume: 227,699
Current Market Cap: $545.7M
For an in-depth examination of EVMN stock, go to TipRanks’ Overview page.